Vanguard Group Inc. Increases Stake in IQVIA Holdings Inc. (NYSE:IQV)

Vanguard Group Inc. boosted its stake in IQVIA Holdings Inc. (NYSE:IQV - Free Report) by 0.5% in the 4th quarter, according to its most recent filing with the SEC. The fund owned 20,131,734 shares of the medical research company's stock after purchasing an additional 105,504 shares during the period. Vanguard Group Inc. owned about 11.09% of IQVIA worth $3,956,087,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds have also recently modified their holdings of the company. GSA Capital Partners LLP acquired a new position in shares of IQVIA in the third quarter valued at approximately $230,000. Pathstone Holdings LLC grew its stake in shares of IQVIA by 4.8% in the third quarter. Pathstone Holdings LLC now owns 14,492 shares of the medical research company's stock worth $3,434,000 after acquiring an additional 667 shares in the last quarter. Prospera Financial Services Inc purchased a new stake in shares of IQVIA during the third quarter worth $245,000. Avior Wealth Management LLC raised its stake in shares of IQVIA by 117.6% in the third quarter. Avior Wealth Management LLC now owns 161 shares of the medical research company's stock valued at $38,000 after acquiring an additional 87 shares in the last quarter. Finally, Advisors Asset Management Inc. grew its stake in IQVIA by 74.3% during the 3rd quarter. Advisors Asset Management Inc. now owns 2,845 shares of the medical research company's stock worth $674,000 after purchasing an additional 1,213 shares in the last quarter. Hedge funds and other institutional investors own 89.62% of the company's stock.

Wall Street Analysts Forecast Growth

A number of analysts have weighed in on IQV shares. Robert W. Baird cut their price objective on shares of IQVIA from $212.00 to $210.00 and set a "neutral" rating on the stock in a report on Tuesday, January 21st. Stephens initiated coverage on IQVIA in a report on Friday, December 20th. They set an "overweight" rating and a $250.00 price target on the stock. Morgan Stanley lifted their target price on IQVIA from $245.00 to $250.00 and gave the company an "overweight" rating in a research note on Tuesday, February 11th. William Blair reiterated an "outperform" rating on shares of IQVIA in a research note on Wednesday, December 11th. Finally, Citigroup lowered their price target on shares of IQVIA from $225.00 to $210.00 and set a "neutral" rating on the stock in a research note on Tuesday, March 4th. Five research analysts have rated the stock with a hold rating, sixteen have issued a buy rating and one has issued a strong buy rating to the company's stock. Based on data from MarketBeat, IQVIA currently has an average rating of "Moderate Buy" and an average price target of $249.05.

Remove Ads

IQVIA Price Performance

Shares of NYSE:IQV traded down $5.04 during trading on Tuesday, hitting $181.07. 1,566,007 shares of the company were exchanged, compared to its average volume of 1,241,421. IQVIA Holdings Inc. has a 1-year low of $179.28 and a 1-year high of $253.84. The company has a quick ratio of 0.84, a current ratio of 0.84 and a debt-to-equity ratio of 2.12. The company has a market capitalization of $31.93 billion, a P/E ratio of 24.14, a price-to-earnings-growth ratio of 1.99 and a beta of 1.50. The business's 50 day moving average is $194.58 and its 200-day moving average is $207.73.

IQVIA (NYSE:IQV - Get Free Report) last issued its earnings results on Thursday, February 6th. The medical research company reported $2.90 earnings per share (EPS) for the quarter, missing the consensus estimate of $3.11 by ($0.21). IQVIA had a return on equity of 28.81% and a net margin of 8.91%. Equities analysts forecast that IQVIA Holdings Inc. will post 10.84 earnings per share for the current year.

About IQVIA

IQVIA Holdings Inc engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.